– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint –
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
Seeking Alpha / 1 hour ago 1 Views
Seeking Alpha / 1 hour ago 1 Views
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint –
Comments